On September 24, 2026, the U.S. Food and Drug Administration (FDA) approved the use of belzutifan in combination with lenvatinib for the treatment of adults with advanced renal cell carcinoma that includes a clear cell component. This approval specifically applies to patients who have previously undergone PD-1 or PD-L1 therapy.

This regulatory decision supports the availability of a new treatment regimen designed to address ongoing therapeutic needs in this patient population. The combination therapy represents a strategic approach targeting cancer progression after initial immunotherapy.

Healthcare professionals should consider this approved combination as part of their treatment planning for eligible patients with this specific form of advanced renal cell carcinoma. The FDA's approval reflects ongoing efforts to expand effective options for complex oncologic conditions.